Printer Friendly

Crescendo Biologics' Second Oncology-targeted Humabody Licensed by Takeda.

M2 PHARMA-July 24, 2019-Crescendo Biologics' Second Oncology-targeted Humabody Licensed by Takeda

(C)2019 M2 COMMUNICATIONS

- Japanese drugmaker Takeda Pharmaceutical Company Ltd. (Takeda), has exercised a second option under its existing, multi-target collaboration and license agreement with UK-based targeted T-cell enhancing therapeutics developer Crescendo Biologics Ltd, Crescendo said.

Takeda has taken an exclusive license to Humabodies directed to another of its oncology targets.

This is the second license option that Takeda has exercised under the agreement with Crescendo and relates to the continued progression of an immuno-oncology programme.

The license marks the successful delivery and further pre-clinical evaluation by Takeda of Humabody leads meeting its stringent criteria.

Takeda's option is part of the existing multi-target collaboration and license agreement announced in October 2016 in which Takeda received the right to develop and commercialize Humabody-based therapeutics resulting from the collaboration.

Under the agreement, Crescendo is eligible to receive clinical development, regulatory and sales-based milestone payments of up to USD 754m plus royalties on Humabody-based product sales by Takeda.

Crescendo Biologics is a T-cell enhancing company. Crescendo develops potent, truly differentiated Humabody therapeutics with a focus on innovative, targeted T-cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA-HSA trispecific for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment.

The molecule if designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity.

The company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody VH).

These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.

Humabody-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Jul 24, 2019
Words:338
Previous Article:LifeSpan BioSciences Releases PathPlus Immunohistochemistry Antibodies for Cancer Targets.
Next Article:Iveric bio Advances LCA10 Minigene Programme and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Programme.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |